drugset / Trial / NCT05608928

Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and Zambia

NCT05608928

RandomizedSingle-groupDouble-blindSupportive care

Summary

This trial will determine if a well-established probiotic, Vivomixx, can modulate the maternal microbiota and ameliorate the maternal environmental enteropathy which compromises growth in the first 1000 days. The probiotic Vivomixx has been used in many thousands of people including pregnant women, both within and outside a research context. This trial is the first in a proposed series of proof-of-concept intervention studies which are intended to provide data to enable a rational selection of interventions to be evaluated at scale in future large scale phase 2 trial in which birth outcomes and postnatal growth will be key endpoints.

Timeline

Start
2022-12-01
Primary completion
2023-05-30
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject VSL#3 Other / unclassified

Indications

No indication recorded.